PT  - JOURNAL ARTICLE
AU  - Kaur, Nirmaljot
AU  - Yarrarapu, Siva Naga S.
AU  - Giri, Abhishek R.
AU  - Rottman Pietrzak, Kathleen A.
AU  - Santos, Christan
AU  - Lowman, Philip E.
AU  - Niaz, Shehzad
AU  - Franco, Pablo Moreno
AU  - Sanghavi, Devang K.
TI  - NOVEL MANAGEMENT OF DEPRESSION USING KETAMINE IN THE INTENSIVE CARE UNIT
AID  - 10.1101/2021.09.23.21262316
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.23.21262316
4099  - http://medrxiv.org/content/early/2021/09/23/2021.09.23.21262316.short
4100  - http://medrxiv.org/content/early/2021/09/23/2021.09.23.21262316.full
AB  - Background Ketamine, a dissociative anesthetic, induces remission of depression by antagonizing glutaminergic NMDA receptors. Ketamine has been used previously in outpatient setting for treatment-resistant depression, but we showcase its utility in depression management at the Intensive Care Unit (ICU).Research Question Can ketamine be used for depression treatment in ICU patients?Study Design and Methods A retrospective chart review of ICU patients was done at a tertiary center from 2018 to 2021, to assess the ketamine usage. Among the patients reviewed, ketamine was used for depression in 12, and for analgesia & sedation in 2322 patients. Ketamine was administered in doses of 0.5mg/kg & 0.75mg/kg for depression. Each course consisted of 3 doses of ketamine administered over 3 days. 7 in 12 patients received a single course of ketamine. The rest received 3-4 courses 1 week apart.Results Ketamine was found to improve mood and affect in most of the patients with depression. 11 in 12 patients had a positive response with better sleep. It has a major advantage over conventional anti-depressants since it takes only a few hours to induce remission. Patients who refused to eat and follow treatment protocol, and who would otherwise succumb to death if not for the rapid remission of depression, were administered ketamine.Conclusion A major drawback of ketamine is that the duration of remission is short, with the response lasting only up to 7 days after a single dose. Hence, all the patients in our study were weaned off ketamine with a supporting antidepressant. Ketamine has been documented to cause cardio-neurotoxicity; however, only one patient had worsening lethargy in our study. To conclude, ketamine has a monumental benefit in treating depression in the ICU. Although our study was associated with positive outcomes, there is a need for prospective studies with long-term follow-up assessments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mayo Clinic institutional review board exempted this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have all data referred to in the manuscript available with us.ICU(Intensive Care Unit)NMDA(N-methyl-D-aspartate)